argenx BV is a global immunology company dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. Through its Immunology Innovation Program (IIP), argenx collaborates with leading academic researchers to transform immunology breakthroughs into a premier portfolio of novel antibody-based therapies. The company is actively evaluating efgartigimod for various serious autoimmune conditions and is advancing several earlier-stage experimental medicines across its therapeutic franchises. With offices located in Belgium, the United States, Japan, and Switzerland, argenx is committed to delivering innovative solutions in the field of immunology.